达沙替尼致可逆性色素脱失的研究进展  

Research progress on reversible hypopigmentation induced by dasatinib

作　　者：吴涛 刘文慧 张曦 Wu Tao;Liu Wenhui;Zhang Xi(Department of Hematology,the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army,Lanzhou 730050,Gansu Province,China;Department of Hematology,Second Affiliated Hospital of Army Medical University of Chinese People's Liberation Army,Chongqing 400037,China)

机构地区：[1]中国人民解放军联勤保障部队第九四〇医院血液科,兰州730050 [2]中国人民解放军陆军军医大学第二附属医院血液科,重庆400037

出　　处：《国际输血及血液学杂志》2023年第5期452-454,共3页International Journal of Blood Transfusion and Hematology

基　　金：甘肃省创新基地和人才计划项目(21JR7RA015)。

摘　　要：第2代酪氨酸激酶抑制剂(TKI)达沙替尼可用于治疗第1代TKI伊马替尼不耐受或耐药的慢性髓细胞白血病(CML)、Ph^(+)急性淋巴细胞白血病(ALL)等血液肿瘤患者。随着达沙替尼临床应用的广泛开展,其治疗相关不良反应逐渐受到关注。过去10年,国内外陆续有达沙替尼治疗后引起患者可逆性色素脱失的散发病例报道。研究发现,达沙替尼主要通过抑制c-Kit导致患者色素脱失发生,且色素变化具有可逆性,在停止TKI治疗后,色素脱失消退。笔者拟就达沙替尼所致色素脱失相关病例及其发病机制的研究进展进行综述,旨在提高临床医师对达沙替尼所致可逆性色素脱失的认识。The second-generation tyrosine kinase inhibitor(TKI)dasatinib can be used to treat patients with hematological malignancies such as chronic myeloid leukemia(CML)and Ph^(+)acute lymphoblastic leukemia(ALL)who are intolerant or resistant to the first-generation TKI imatinib.With the extensive clinical application of dasatinib,its treatment-related adverse reactions have been gradually attracted attention.In the past decade,sporadic cases with reversible hypopigmentation caused by dasatinib treatment have been reported both domestically and internationally.Studies have shown that dasatinib causes hypopigmentation mainly by inhibiting c-Kit,and the pigment changes are reversible,and the hypopigmentation disappears after stopping dasatinib treatment.This article intends to review research progress of dasatinib-induced hypopigmentation-related cases and their pathogenesis,in order to improve clinicians'understanding of dasatinib-induced hypopigmentation.

关 键 词：酪氨酸蛋白激酶抑制剂 达沙替尼 色素沉着不足 黑素细胞 可逆性 

分 类 号：R969[医药卫生—药理学]